Phase 3
Completed N=2,539
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
Overweight · Obesity
Source: ClinicalTrials.gov NCT04184622 ↗
Enrolled (actual)
2,539
Serious AEs
8.7%
Results posted
Apr 2023
Primary outcomePrimary: Percent Change From Baseline in Body Weight (Primary Treatment Period) — -2.4; -16.0; -21.4; -22.5 percent change — p=<0.001
◆ Published Evidence
Emerging
1citation · ~1 / year
Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.
Summary
This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase. The main phase of the study will last 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.
Linked Publications (5)
-
Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.
-
Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.
-
Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials.
-
Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT-1 Trial.
-
People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Change From Baseline in Body Weight (Primary Treatment Period) |
-2.4; -16.0; -21.4; -22.5 | <0.001 sig |
| PRIMARY Percentage of Participants Who Achieve ≥5% Body Weight Reduction (Primary Treatment Period) |
27.87; 89.41; 96.18; 96.32 | <0.001 sig |
| SECONDARY Change From Baseline in Body Weight (Pooled Doses of Tirzepatide 10 mg and 15 mg) - Primary Treatment Period |
-2.5; -13.2 | <0.001 sig |
| SECONDARY Percentage of Participants Who Achieve ≥10% Body Weight Reduction (Primary Treatment Period) |
13.54; 73.35; 85.85; 90.08 | <0.001 sig |
| SECONDARY Percentage of Participants Who Achieve ≥15% Body Weight Reduction (Primary Treatment Period) |
5.98; 50.24; 73.61; 78.24 | <0.001 sig |
| SECONDARY Percentage of Participants Who Achieve ≥20% Body Weight Reduction (Primary Treatment Period) |
1.26; 31.62; 55.48; 62.88 | <0.001 sig |
| SECONDARY Change From Baseline in Waist Circumference (Primary Treatment Period) |
-3.4; -14.6; -19.4; -19.9 | <0.001 sig |
| SECONDARY Change From Baseline in Short Form Survey-36 Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score at Week 72 (Pooled Doses of Tirzepatide 10 mg and 15 mg) - Primary Treatment Period |
1.7; 4.0 | <0.001 sig |
| SECONDARY Percent Change From Baseline in Triglycerides (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period |
-6.3; -27.6 | <0.001 sig |
| SECONDARY Percent Change From Baseline in Total Cholesterol (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period |
-1.11; -5.97 | <0.001 sig |
| SECONDARY Percent Change From Baseline in High-Density Lipoprotein (HDL) Cholesterol at Week 72 (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period |
0.25; 7.92 | <0.001 sig |
| SECONDARY Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period |
-1.3; -8.1 | <0.001 sig |
| SECONDARY Percent Change From Baseline in Fasting Insulin (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period |
-9.7; -46.9 | <0.001 sig |
| SECONDARY Percent Change From Baseline in Body Weight (Primary and Additional Treatment Periods : Participants With Prediabetes at Randomization) |
-2.1; -15.4; -19.9; -22.9 | <.0001 sig |
| SECONDARY Percentage of Participants With Onset of Type 2 Diabetes From Baseline to Week 176 (Primary and Additional Treatment Periods: Participants With Prediabetes at Randomization) |
12.6; 1.2 | <0.0001 sig |
| SECONDARY Percentage of Participants With Onset of Type 2 Diabetes From Baseline to Week 193 (Primary and Additional Treatment Periods + Safety Follow-up Period: Participants With Prediabetes at Randomization) |
13.7; 2.4 | <0.0001 sig |
| SECONDARY Change From Baseline in Body Mass Index (BMI) - Primary Treatment Period |
-0.9; -5.9; -8.1; -8.6 | <0.001 sig |
| SECONDARY Change From Baseline in Hemoglobin A1c (HbA1c) - Primary Treatment Period |
-0.07; -0.40; -0.49; -0.51 | <0.001 sig |
| SECONDARY Change From Baseline in Fasting Glucose (Primary Treatment Period) |
0.86; -7.73; -9.73; -10.55 | <0.001 sig |
| SECONDARY Percent Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period |
-0.85; -6.86 | <0.001 sig |
| SECONDARY Percent Change From Baseline in Very Low-Density Lipoprotein (VLDL) Cholesterol (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period |
-5.6; -27.6 | <0.001 sig |
| SECONDARY Percent Change From Baseline in Free Fatty Acids (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period |
6.1; -5.9 | <0.001 sig |
| SECONDARY Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period |
-1.0; -5.3 | <0.001 sig |
| SECONDARY Percentage of Participants Who Achieve ≥5% Body Weight Reduction (Primary and Additional Treatment Periods : Participants With Prediabetes at Randomization) |
24.62; 90.61; 91.92; 94.78 | <.0001 sig |
| SECONDARY Change From Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score at Week 72 (Primary Treatment Period) |
10.1; 17.8; 20.7; 21.8 | <0.001 sig |
| SECONDARY Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Tirzepatide (Primary Treatment Period) |
88900; 177000; 266000 | — |
Eligibility Criteria
Inclusion Criteria
- Body mass Index (BMI) ≥30 kilograms per square meter (kg/m²), or ≥27 kg/m² and previous diagnosis with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease
- History of at least one unsuccessful dietary effort to lose body weight
Exclusion Criteria
- Diabetes mellitus
- Change in body weight greater than 5 kg within 3 months prior to starting study
- Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity
- History of pancreatitis
- Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
- History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years
- Any lifetime history of a suicide attempt
Data sourced from ClinicalTrials.gov (NCT04184622) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.